Bridging Science & Business: A Real-World Approach with Kevin Scanlon
E13

Bridging Science & Business: A Real-World Approach with Kevin Scanlon

Heath Fletcher:

Hey. Welcome to this episode. My guest today is doctor Kevin j Scanlon. He is a scientist, an inventor, an entrepreneur, an author, and an investment adviser. Not only that, he is from New York, lives in California, and has an Irish passport.

Heath Fletcher:

So we're gonna have a fun conversation. Let's get on with it. So, Kevin, thank you for joining me on this episode. Really appreciate you taking the time today to share with us a little bit about you and your expertise and what you've been doing lately. So let's start with that.

Heath Fletcher:

Tell us about yourself and and what you've been up to.

Kevin Scanlon:

So I was born in New York City. I was educated in London, and I have an Irish passport.

Heath Fletcher:

Oh, wow.

Kevin Scanlon:

So I I was trained in molecular biology and cancer research. I was, fortunate I was at Yale, trained with Joe Bertino in drug resistance in patients with cancer. And then I went into the pharmaceutical industry and ran a cancer program for a German pharmaceutical company. And when I finished there, I went into the investment community because I could speak science and I could speak business. And I wound up becoming chairman of the Pasadena Angels, and I was also with the the second group, Tech Coast Angels.

Kevin Scanlon:

And I helped entrepreneurs and investors understand the risks of investing in science companies, technology companies. And when I after being chairman, I started teaching because I realized the entrepreneurs were so did not understand the process of getting funded by investors. So I wrote a book called the hybrid entrepreneur for the students so they could understand the process of starting a company and getting funding. And that's what I've been doing. So I've been advising companies and investors on good good investments for startup companies.

Heath Fletcher:

Interesting. So you'd you talked about risks. What were some of the key risks that you were trying to help steer them around?

Kevin Scanlon:

It was an interesting problem. The scientists or technologists had no understanding of the vocabulary of the businessperson, and that scared them, raised their anxiety. The businessperson had no idea of what the technologist was saying because it sounded all gibberish to him. So his anxiety went up. So the point of the book was to help understand the process, help understand the vocabulary.

Kevin Scanlon:

Once that was achieved, then you introduced the lawyers with their vocabulary, and everybody became anxious.

Heath Fletcher:

And confused and scared. Exactly. It's funny that this isn't an unusual conversation. I mean, actually, in marketing, we run into the same thing where you've got multiple people at the table speaking different languages from their area of expertise. And and and marketers have to try and crunch that and make that attractive and and the messaging reach the right audiences.

Heath Fletcher:

So I I can relate to that situation.

Kevin Scanlon:

Yes. So it it it's important to understand. If they understand the process and they understand where each group is coming from, then it makes it easier. Not solved, but it makes it easier to communicate between three groups or more.

Heath Fletcher:

Right. And if you can let the if you can let the scientists focus on the science, then, you know, what they're actually trying to create will actually get better rather than distracting them with all this business mumbo jumbo.

Kevin Scanlon:

Yeah. To a certain degree. Yes. That's true.

Heath Fletcher:

And the Opacity of the Angels is still up running. It's been going for twenty four years, I was reading. So tell me a little bit more about that organization.

Kevin Scanlon:

It's it's a very interesting organization. It's about a 100 investors with domain experience, c suite experience that work together as a group to invest in early stage companies. We fund about 20 companies a year, and we review about 600. So that gives you a proportion.

Heath Fletcher:

Wow.

Kevin Scanlon:

It's an involved process. What we try to do is we try to mentor the entrepreneur and help them because, as I've always said, if the company was perfect, there would be no need to go to angel investors.

Heath Fletcher:

Right. Of course. Good point.

Kevin Scanlon:

So what we try to do is look at the company, see if it's a good fit for our members, see if our members can mentor or help or network to make the company successful in addition to helping them get funded. That's smart.

Heath Fletcher:

So you're actually so you're actually investing in their in the in the ideas behind the growth as well. Right?

Kevin Scanlon:

Because Yes. If they're successful if they're successful, we're successful.

Heath Fletcher:

We're successful. Very good. Excellent. Wow. And you've been with that organization from from the beginning?

Kevin Scanlon:

No. Not quite. Dwayne Peterson and Al Schneider started it in around February. I joined around 02/2004. They were fascinated that I could speak science and I could speak business.

Kevin Scanlon:

So when they found that out, they the Tech Coast Angels immediately said, you're gonna join our group also.

Heath Fletcher:

Oh, right. It's okay. What's the name of that group again? Tech Tech Tech

Kevin Scanlon:

Coast Angels. Yeah. The Tech Coast Angels.

Heath Fletcher:

Tech Coast Angels. Got you.

Kevin Scanlon:

So and it's the largest investment group angel investment group in The United States. And so I had the opportunity to sit every month with the Pasadena Angels and see the companies they screened, and every month, sit with the Tech Coast Angels and see what companies they screened. And then I was able to listen to the investors' questions. And if I didn't understand the investors' questions to the entrepreneurs, I would go up to the investors and say, what why was that question so important to

Heath Fletcher:

you? Right.

Kevin Scanlon:

And he would explain it. So I had an education in 200 people with their background and knowledge.

Heath Fletcher:

So you're like a liaison between investor and and company owner or founder or whatever. Interesting.

Kevin Scanlon:

Yeah. Yeah.

Heath Fletcher:

Isn't that interesting? What were some of the what were some of the the key hiccups around that?

Kevin Scanlon:

Well, it was personality. It was personality. It was it was fascinating. One of the things we like to do is we like to see the interaction of the management team in the presentation to the investors Right. Because that tells us a lot.

Kevin Scanlon:

In in the book I I wrote, there are usually two reasons why companies fail. They run out of money, or the culture does not change with the growth of the company.

Heath Fletcher:

Very interesting. Great.

Kevin Scanlon:

So what we like to look at is the dynamic. Is the dynamic good? Are they listening? And, you know, you're sitting in a room with 50 to a 100 investors who have anywhere from ten to fifty years experience, who have enormous networks. And if the entrepreneur tries to BS any of these people, it's just it's ridiculous.

Kevin Scanlon:

So we're we're there to help you, and you have to be honest and say, look. My company has a floor or weakness, and this is what we need. Can you help us? So those were the most receptive entrepreneurs that we tried to work with. Conversely, there were other entrepreneurs that said, no one could understand my product better than me.

Heath Fletcher:

Yeah. Red flag.

Kevin Scanlon:

Yeah. Red flag. So we passed on them. So it was a question of developing a connection, a personal interaction with the entrepreneur, with the investor to help mentor them, to open them up to the the investors' networks, to make them successful. And, if they were successful, we would be successful because our priority was get a good return on investment as soon as possible so we can reinvest again.

Kevin Scanlon:

What I realized was that the entrepreneurs did not really understand what was going on with the investors. And the investors were just like, why doesn't this entrepreneur get it? And that's why I wound up at when I became emeritus chairman at Pasadena Angels, that's why I decided to write the book. I thought the biggest contribution I could make would be to help the entrepreneur understand the process, understand the vocabulary to be more successful. And it's worked to a certain degree.

Heath Fletcher:

Right. The and, of course, that's what you were teaching too. Right?

Kevin Scanlon:

Yes. I I was fortunate. I I moved to Boston for eight years, and I wound up in the business school without an MBA, which annoyed a lot of people. And I taught a course on entrepreneurship. There wasn't a lot of entrepreneurship going on.

Kevin Scanlon:

So what we did was I I taught about 600 students, and we actually took a 100 university companies and put them into the course. So I'd have the students form a team. They would then go to the CEO, talk to the CEO, find out what the product was, come back, and then for fourteen weeks, do research on the company, the product, the business model, the finances. And at the end of the fourteen weeks, the CEO would get business plan, customer survey, PowerPoint presentation to investors, and a term sheet Wow. For free.

Heath Fletcher:

For free. That's just like a, yeah, a free think tank.

Kevin Scanlon:

Yes. So and it was a win win for everybody because the students got to be a team and evaluate the company. The students we had four to six companies each semester, so they would see four to six different companies with different problems, and then the CEO would get it. Now at first, they didn't the CEO didn't believe it was free, and then didn't believe that they could do anything of any consequence.

Heath Fletcher:

Right. What a huge learning experience for those students, though, to actually work with a real company with a real CEO and yeah. What a great opportunity.

Kevin Scanlon:

Yeah. So it it the majority of the students really appreciated it.

Heath Fletcher:

I bet.

Kevin Scanlon:

And the majority of the CEOs really appreciated it. So I

Heath Fletcher:

had because I now learned go ahead.

Kevin Scanlon:

Go ahead. Some CEOs actually hired the students into their company.

Heath Fletcher:

Oh, wow.

Kevin Scanlon:

But I had other CEOs that looked at it and said, there's no way that they could understand more than I know about my company and my product, and they would throw it in the rubbish bin.

Heath Fletcher:

Wow. Red flag.

Kevin Scanlon:

Exactly. This is leftover from the investors.

Heath Fletcher:

Exactly. That's the same guy.

Kevin Scanlon:

Yeah. Probably was.

Heath Fletcher:

So then all that learning for you, I was learning for you too and pulling all that information was what actually helped you put the book together too.

Kevin Scanlon:

Yeah. What was really fascinating was each semester the book took about six years to write.

Heath Fletcher:

Right.

Kevin Scanlon:

Each semester, would go back over the questions that the students were asking, and I would say, that question really doesn't make any sense to me. Why is it so obvious to me but not obvious to them? And then I began to realize where they were coming from and what they knew and what they didn't know. So that helped a lot by going over the questions. So I I evolved the book into addressing a lot of those questions that someone early on in their career being an entrepreneur faced the same sign kind of questions or needed that information.

Kevin Scanlon:

So that that helped a lot.

Heath Fletcher:

Right. So what you're talking about we're talking about personality and culture. You said that's kind of one of the top issues that people look for look out for when they're looking to invest. And and, you know, you you identified that that same problem, you know, with the students working with these CEOs. How if if we're talking about one of these CEOs who just thinks that no one else can solve my problems, no one else knows my what I do better than me, how does that person, that CEO, how do they succeed?

Heath Fletcher:

How do they move forward? Do they just at some point, do they have to get out of the way?

Kevin Scanlon:

Yeah. We've seen a lot of this in the investment community. We've so, like I said, if if an an entrepreneur behaves like that, that's a red flag to us, and we just move on to the next company. Sometimes we have CEOs, entrepreneurs that will accept it, they have to kind of trust you so that that the trust becomes the issue. Will the CEO trust a bunch of old white guys over 60 years old with domain experience.

Kevin Scanlon:

And, you know, that's the biggest challenge for the entrepreneur. So it's really finding the right fit, finding the right fit of the investment group, the right fit of the mentors, and the right fit with the entrepreneur. And if you can put that together, then you can usually have a successful company.

Heath Fletcher:

Right. Right. It's interesting you brought up trust too because as much as it you might be thinking, well, that that entrepreneur just has too big of an ego to work with. But it may not be as much that as much as they don't trust anybody. Right?

Heath Fletcher:

Which could actually feed into the culture of their staff as well. If they don't trust an investor, how are they ever gonna trust a a staff member or a man or someone on their management team. Right? That could be the core issue there is that they just don't trust anyone to have their product or service or business in in in their on their hearts.

Kevin Scanlon:

So What what we saw a lot, especially because I looked at all the technology companies, the science companies, it was patent issues. So a lot of times with early stage companies, entrepreneurs have filed a patent, but it's not been issued.

Heath Fletcher:

Right.

Kevin Scanlon:

So they're very paranoid that somebody can steal their ideas.

Heath Fletcher:

Right. Very protective. Yeah.

Kevin Scanlon:

So from their point of view, I I can understand that. So what I always use to say is, look. I don't wanna know the patent. I don't know wanna know the claims. But can you tell me what your company does, what your product does in a way that doesn't disclose confidential information?

Kevin Scanlon:

And that was a big trick for me because if they couldn't do it, then I knew this was not gonna be a good company that I was gonna be able to run with.

Heath Fletcher:

Right. Right.

Kevin Scanlon:

So they you know, I gave them the opportunity to explain in layman's terms why their product was so important without disclosing confidential information. Most of them could, some of them couldn't.

Heath Fletcher:

And did you ever run into an entrepreneur who had such a great idea, had such a such a worthy investment, but maybe kinda had some of these neuroses about not letting anyone in or not, that you just actually couldn't let them go, that you really tried to get them through the other side?

Kevin Scanlon:

So we had a rule in the investment community. We would rather fund a first class team and a second rate product than a first class product and a second rate team. And the and the reason for that is most concepts, most minimum viable products are going to ultimately change by the time it gets to the market and the customer. And so the team has to be able to pivot. Pivoting was is very critical because most concepts to product is very rarely a straight line.

Kevin Scanlon:

So we need a team that can pivot, that can evaluate, and be self critical, and find the best product for the best cup customer for the best market.

Heath Fletcher:

A team that can see its own weaknesses and faults and and areas that need improvement. Yeah. Yeah. That's a good point. Yeah.

Heath Fletcher:

That's a wise rule.

Kevin Scanlon:

Read my book.

Heath Fletcher:

Did you follow it? Did you follow it well? It

Kevin Scanlon:

was Well, that that is a good question to ask.

Heath Fletcher:

Did you follow your own rule?

Kevin Scanlon:

That is a good question to ask. The joke among the investment community is if you have an MD or a PhD, you're the worst investors in the group. So I had to be really careful because I was very critical of the science. I mean, people came to me all the time with a cure for cancer. And I I knew that it would be very, very rare if it was true.

Kevin Scanlon:

So I had to be calm and and stay focused.

Heath Fletcher:

Right.

Kevin Scanlon:

There was once or twice. The problem with science is it's early stage science is a gamble. Is it gonna be the product that you think it's gonna be, or is it gonna bomb? And the science, as most scientists know, a lot of the experiments fail. So twice, I was caught with falling in love with one, the idea, and second, the data was, early stage data was very encouraging.

Heath Fletcher:

Right.

Kevin Scanlon:

Bombed. Darn. Ugh. And I would have a lot of the investors come to me and say, Kevin, what do you think? What do you think about the science?

Kevin Scanlon:

So I developed a system where I would say, this is what I think is strong. These are the positive aspects of this product. These are the weaknesses, and here's the risk.

Heath Fletcher:

Right.

Kevin Scanlon:

So if you're willing to take the risk, then so that's the only way I was able to survive twenty years as an investor.

Heath Fletcher:

Right. Well, it's it that's an educated decision then. And once you know all those things, then it's an educated decision. And, you know, like you say, high risk, high reward. Right?

Heath Fletcher:

So if you're willing to throw the dice and you have the bandwidth to to do it, then, you know, take a shot.

Kevin Scanlon:

Yep.

Heath Fletcher:

But if you're looking for something a little more sound, a little more reliable, then you kinda gotta you just use the information, like you said, to make your decision.

Kevin Scanlon:

Well, there's another interesting problem.

Heath Fletcher:

Okay.

Kevin Scanlon:

So if you wanna do a therapeutic or a medical device, you have to go through the FDA.

Heath Fletcher:

Right.

Kevin Scanlon:

In Southern California, they're way adverse to medical way adverse because of the FDA, they're not familiar with the FDA. Conversely, in Boston, which is a hotbed of medical research

Heath Fletcher:

Right.

Kevin Scanlon:

They don't think twice about funding a therapeutic.

Heath Fletcher:

Okay.

Kevin Scanlon:

And so when I moved to Boston, I was sitting with one of the angel investment groups, and the chairman was next to me. And we were talking, and they went through eight companies, medical companies. And in Southern California, we would see one a month, and here I'm seeing eight.

Heath Fletcher:

Eight. Jeez. Wow.

Kevin Scanlon:

What a to the chairman, and I said, this is a lot of medical companies that you're reviewing. And I said, at least every company has one someone associated with MIT. He looks at me and says, yeah. He says, only fund MIT. Right?

Kevin Scanlon:

Science.

Heath Fletcher:

Oh, really?

Kevin Scanlon:

Which again yeah. MIT science is really, really strong, and the high probability of a product coming out is very, very strong. And, yes, if you're gonna put your money in, the odds are that you're gonna get something. But Right. In Southern California, if you talk FDA, they don't wanna hear about it because they would rather do some electronics, which you will know in six to eighteen months when the product and the customer is working, whereas a therapeutic would take ten years.

Heath Fletcher:

Amazing. Can you tell me this may be slightly off topic, but there seems to be a lot more, flexibility in the laws in the medical health care world in Arizona than other states?

Kevin Scanlon:

Well, first, you have the FDA and the National Institute of Health.

Heath Fletcher:

Right.

Kevin Scanlon:

So it's out of federal

Heath Fletcher:

across the board. That's Across

Kevin Scanlon:

the board. That that's that's the standard for the country. Right. Then individual states do have different criteria and different standards.

Heath Fletcher:

Okay.

Kevin Scanlon:

So and I will tell you, there's a big difference between East Coast and West Coast. Yeah. Even taking an example of COVID, How Boston dealt with COVID and how Los Angeles dealt with COVID were completely different.

Heath Fletcher:

Is that right? Yeah.

Kevin Scanlon:

Now you have to remember that Boston has 10 medical institutions with, you know, a high level of biotechnology going on.

Heath Fletcher:

Right.

Kevin Scanlon:

So it's very easy to consult with the doctors at Harvard, Mass General, all of the different hospitals, and get an an opinion that's very good. Whereas it's a little bit more limited in in California and Southern California.

Heath Fletcher:

California.

Kevin Scanlon:

So Arizona may have different criteria.

Heath Fletcher:

Oh, okay.

Kevin Scanlon:

Just not familiar with it.

Heath Fletcher:

Okay. Alright. That was a side a side jar. So you there's another organization I saw on your on your profile called International Bioscience. What's that all about?

Kevin Scanlon:

A long time ago in a faraway place.

Heath Fletcher:

In a faraway galaxy?

Kevin Scanlon:

Yeah. Something like that. I I decided I've been invited by many countries to advise on their science and their business and their entrepreneurship and their angel investing. So places like Australia, New Zealand, China, Singapore, Japan. So that's why I made I just made the company for that because I Okay.

Kevin Scanlon:

Consulted for companies. So I've been to New Zealand about a dozen times.

Heath Fletcher:

Is that right? I've been there too. I love it there.

Kevin Scanlon:

Spectacular. It's just and the people are so nice. And the the government was faced with a problem after they their major export to was to England. And when England joined the EU, they got crashed. So that interestingly, the treasury department in New Zealand was the one that organized innovation entrepreneurship startup to encourage the universities.

Heath Fletcher:

Oh, wow.

Kevin Scanlon:

Conversely, in Ireland, the government went to the Department of Education and said, no. No. No. What we're gonna do is we're gonna educate our students into the pharmaceutical industry to make it a place for the Americans to bring their industry.

Heath Fletcher:

And each

Kevin Scanlon:

con each country approached it very differently. I I found that's the thing I found most interesting, on how to survive economically and keep their country ahead of the economic changes that were going on in the world

Heath Fletcher:

Right.

Kevin Scanlon:

In the '20 over the last twenty years.

Heath Fletcher:

What are some of the most fascinating stories that came from that? If if one doesn't pop out, don't worry about it.

Kevin Scanlon:

It was fascinating. Each country had their own culture. And what they would accept and what they wouldn't accept because I was able to compare several different countries, governments. Why it would work in one company wouldn't work in another company. I it made no sense to me at that level.

Kevin Scanlon:

And then when the government decided to push down into the universities, it was a completely different ballgame. Nobody wanted to listen to the government.

Heath Fletcher:

Free will to the universities.

Kevin Scanlon:

Yeah. So they bring in these experts. They, you know, they talk to them. I mean, I met with the faculty in several different countries, And they some of them just blew me off. Like, you don't know what you're talking about.

Kevin Scanlon:

This is this is my country. I know what's best, you know, just like entrepreneurs.

Heath Fletcher:

Right. Right. It sounds like a familiar story.

Kevin Scanlon:

Yeah. There's no way that you could know more about this than I do. So there was a lot of pushback there, but there was some acceptance and some people and I still have contacts with them. But, like, in China and Japan and Singapore, New Zealand, Australia, they it's it's human nature. That's all I

Heath Fletcher:

can Yeah. Human nature. Yeah. You're right. Okay.

Heath Fletcher:

Coming back to Tech Coast and Pasadena Investment Groups. When you guys were how did how did an entrepreneurs present? Was it kinda like a dragon's den, sharks den kind of approach? How did they how did they what how did they prepare and how did they actually get in front of you?

Kevin Scanlon:

Shark Tank.

Heath Fletcher:

Shark Tank. Okay.

Kevin Scanlon:

The producers of Shark Tank came to our investment group and said, we're gonna do a TV series on Shark Tank. How do you guys work?

Heath Fletcher:

They asked you.

Kevin Scanlon:

They no. They came and they watched.

Heath Fletcher:

Wow. That's what they you were the you were the the test pilot. Yeah. Wow. Interesting.

Kevin Scanlon:

Yeah. One of the producers asked me, would I be interested in being on, you know, one of the judges? And I said, no. No. And then they said, well, didn't do it.

Kevin Scanlon:

No. Absolutely not. And then they said, well, you have a company. Do you wanna put your company forward? I said, no.

Kevin Scanlon:

Absolutely not. What? So yes. So for the last, what, ten years, fifteen years, everybody comes to me and says, is that what your investment group is like, Shark Tank?

Heath Fletcher:

Isn't that funny?

Kevin Scanlon:

And I go, no. Sorry. It's not. That's TV.

Heath Fletcher:

But Shark Tank is a is a is a somewhat of a representation of what you process. Right?

Kevin Scanlon:

So you have four anywhere from four to eight people, and they only present the entrepreneur presents for, like, two minutes, five minutes. Yeah. Our process is we screen every company that submits to the website, Then we have a committee the next week that reviews all the applications, and then we pick the top four. And the top four come and present to the preliminary group. And then we we have one or two go on to the main monthly meeting to present.

Kevin Scanlon:

And of that, then we move on to due diligence. It's a whole month process.

Heath Fletcher:

Quite a process.

Kevin Scanlon:

Yeah. Yes. So we we we don't shoot from the hip, and we don't. No. We do a lot of due diligence.

Heath Fletcher:

Well, going from 600 applicants to 20 recipients is quite a big step.

Kevin Scanlon:

Yeah. We have to make sure that, you know Yeah. We what they're saying is right, what they're documenting is right Mhmm. That they are protected. And if we put money into the company, you know, we're not putting it into some less than honorable investment.

Heath Fletcher:

And I'm I'm sure once they're awarded, then there's obviously some sort of criteria and milestones and ongoing back and forth over during the as part of

Kevin Scanlon:

the process. That's what we've introduced in the last ten or twenty years is we have milestones, timelines, and investment. And sometimes if we're a little nervous, we tranche the money matching the milestones and the timelines.

Heath Fletcher:

Right.

Kevin Scanlon:

Now I will tell you, whatever they say they need is never enough.

Heath Fletcher:

Double it.

Kevin Scanlon:

Yes. That's that's what I always used to say. Whatever you're telling me, you need twice as much. And then I say, how long is this gonna take? And they go, oh, six months, twelve months.

Kevin Scanlon:

We'll have it done by eighteen months. And I said, nope. It's gonna take twice as long.

Heath Fletcher:

Double it.

Kevin Scanlon:

And and I was the most optimistic investor. And the track let let the track record show, yes, it went even longer and cost more money. Right. But, you know, it's to be expected because they're doing unknown things.

Heath Fletcher:

Yeah. And you're probably introducing a lot of steps and variables and checkpoints that they never even thought of. Right? Exactly. They're just like, let's get to market.

Heath Fletcher:

And and you're like, okay. Hold on. Hold on. We got a lot of we got some other things to consider along the way. So Yeah.

Kevin Scanlon:

She and sometimes they just like to take the money and run. And we got Right. No. No. No.

Kevin Scanlon:

We've done that before. It doesn't work.

Heath Fletcher:

Yeah. You so you learned along the way too.

Kevin Scanlon:

Oh, we yeah. It's the growth curve was exponential.

Heath Fletcher:

Yeah. No doubt. Well, I mean, you got the experts at the table. It's it makes sense to actually have that sort of magnifying glass on what these what these people are doing with with the money that's being funded to them.

Kevin Scanlon:

So Yeah. What surprised me the most is over the ten years that I was actively involved with Pasadena and Tech Host Angels, of which we looked at 1,500 to 2,000 companies, you know, every couple of months. Never did we have a company present that in the audience, there wasn't an investor that was a domain expert.

Heath Fletcher:

Really?

Kevin Scanlon:

I I was most impressed with that. They would. Every entrepreneur that came before the group, there was always somebody in the group that was a domain expert on the product customer market.

Heath Fletcher:

Interesting. Well, that's what you need, really.

Kevin Scanlon:

Exactly. Exactly. And so everybody would turn to the person and say, what do you think?

Heath Fletcher:

What do you think? Yeah.

Kevin Scanlon:

And then let me check my network. Let me see what we got.

Heath Fletcher:

So now they're in the mix. They got awarded. They've been selected. There's all these, there's a plan in place for rolling this out. Where do you find where do you find often is there's a roadblock for them?

Heath Fletcher:

Assuming they're almost to market, where do you find they where is there where there's almost a roadblock?

Kevin Scanlon:

The two factors. They run out of money. We have to do bridge funding, or what's happened in the last five or ten years is the venture capital has now derisked some of those investments, so they co invest with the angels to keep things going. Mhmm. So angel and VC investors with a company for bridge funding till they get the product to market, that's usually the best.

Kevin Scanlon:

Mhmm. But the second problem is the team that starts initially, and then they start growing the team to a point where, you know, they have enough money to get the product to market. We find one of the biggest problems is a cultural difference.

Heath Fletcher:

Mhmm.

Kevin Scanlon:

And the expectations are different. So if we have three founders, the three founders start quibbling with each other.

Heath Fletcher:

Oh, right.

Kevin Scanlon:

Because, oh, I I did more than you did. Or, you know, I should have a third of the company.

Heath Fletcher:

They're seeing the light at the end of the tunnel, and they wanna Right.

Kevin Scanlon:

And then as as the company cult grows, the culture becomes more and more fractionist. Mhmm.

Heath Fletcher:

Now you've got a now you've got toxic culture at the top.

Kevin Scanlon:

Yeah. So now we have fighting.

Heath Fletcher:

And Yeah.

Kevin Scanlon:

That that's just not good. And that's a red flag.

Heath Fletcher:

Yeah. No doubt. Do you ever find that when you're close to getting to market, all of a sudden entrepreneurs now become graphic designers and website developers and Yeah. Professional marketers. All of a sudden, they just have this hidden agenda and creative streak.

Kevin Scanlon:

You have no idea how true that is, both for the entrepreneur and the investor.

Heath Fletcher:

Oh, my gosh. Both of them. Yeah. No doubt. Yeah.

Heath Fletcher:

Hey. I've been thinking of a logo for this for the last nine years.

Kevin Scanlon:

Yeah. So we have that problem with the startup company that everybody thinks they can do everything. Yeah.

Heath Fletcher:

Right.

Kevin Scanlon:

The the biggest challenge I had as chairman of the Pasadena Angels was marketing people thought they were IP attorneys.

Heath Fletcher:

Oh, yeah. That too. It goes the other way around.

Kevin Scanlon:

The IP attorney thought that they were marketers.

Heath Fletcher:

Oh, yeah.

Kevin Scanlon:

I I would have to call time out, and I would say, why don't we leave that to the expert?

Heath Fletcher:

Yep.

Kevin Scanlon:

But, yeah, everybody's everybody's got their own opinion. Everybody's got their own idea, and everybody wants

Heath Fletcher:

to

Kevin Scanlon:

it's an opportunity then for them to talk. So I was managing cats in an investment group with a 100 investors. And, you know, everybody everybody had to have their time.

Heath Fletcher:

Yeah. The framers are working on electrical. Electricians are working on the plumbing, and plumbers are putting in insulation.

Kevin Scanlon:

It would seem reasonable, wouldn't it?

Heath Fletcher:

Why not? You know? How hard can it be?

Kevin Scanlon:

Yeah. The the biggest flaw that we saw in a lot of the companies was financial.

Heath Fletcher:

Yeah.

Kevin Scanlon:

So a lot of the scientists and technologists were very good at what they did and the product and the need for the customer. But when it came to giving me a financial strategy, it a lot of times, was just BS.

Heath Fletcher:

Right. Right. And that's a tough that's a tough spot to be in.

Kevin Scanlon:

Yeah. So we try to help them with financial guides or, you know, say, look, you know, this is not gonna fly. Before they present to the the group, you're gonna have to work on your financials.

Heath Fletcher:

Right. Oh, yeah. That's a good that was a good question. So you have this you have these 600 applicants, 20 make it through, then you got 580 who still have these ideas. Do you ever go back to the ones that, you know, that almost made it?

Heath Fletcher:

You know, the 579? Or

Kevin Scanlon:

What we do is if we like the company, but they didn't make the cut in that month's screen, we take someone who's a domain expert, an investor, and then we match them up and say, why don't you mentor this company for six or twelve months and then come back? So we always leave the door open. You know, the company has an opportunity to mature.

Heath Fletcher:

Right.

Kevin Scanlon:

And we try to give them and we try to give them up, our investors, who have domain experience to help them.

Heath Fletcher:

So they can re they can resubmit?

Kevin Scanlon:

And Yeah. Yeah.

Heath Fletcher:

Do you feel like you can name a few of your favorite outcomes, favorite products or businesses over the years?

Kevin Scanlon:

One of my favorite, and I wasn't involved in this, It was after I joined, was a company that wanted to make credit cards. So you would have cash. You would have credit cards. And the strategy was that parents could give that little credit card to their kids when they were off to college, and they would have cash and control the volume. And the CEO was a DJ and pulled together some people and worked out of a garage and put this money together.

Kevin Scanlon:

And he worked on it for about two years, and he was not getting any traction at all. And what happened was he went to New York to a VC to get some money. It was like Friday night. It was raining. The VC said, no.

Kevin Scanlon:

I'm not interested in that at all. He'd been around for two years trying to get money. Calls his wife and says, it's over. We're gonna have to sell the house. Company's not gonna make it.

Kevin Scanlon:

Comes home. On that Saturday morning, he gets a phone call from a Tech Coast Angel member and says, is that deal still on the table? And the guy goes, well, it's almost closed, but we can work something out for you.

Heath Fletcher:

As he's like

Kevin Scanlon:

Yes. So Tech Coast Angels went in for a small round about 10 or 15 investors for about $250,000, got them up, got some good mentoring, got them out of the garage.

Heath Fletcher:

Amazing.

Kevin Scanlon:

Kept going, came back for another round, kept going. They did an IPO for a billion dollars three years later.

Heath Fletcher:

Wow. No kidding.

Kevin Scanlon:

That was a home run.

Heath Fletcher:

There's a success story. Wow.

Kevin Scanlon:

So I go I go to everybody that invested. I go to the people that didn't invest, and I said, why didn't you invest in this? You got a 100 200 fold return on investment. He said, are you kidding? He was a DJ.

Kevin Scanlon:

What did he know about finance? I went to the

Heath Fletcher:

other group. See?

Kevin Scanlon:

I went to the other group, and I said, well, why did you invest? And some said they liked him. Some thought it was an interesting idea. Some said, I had some extra cash on the table, so I I just invested in it.

Heath Fletcher:

And and he must have had a bit of passion. You know? I mean, when you talk about person and it's like we're He

Kevin Scanlon:

was able to keep everything together. Yeah. It was just amazing. I met him a couple of times and had lunch with him, and the guy was just a really well down to earth guy. Nice.

Kevin Scanlon:

And he Yeah. No matter what hit him, he just kept going. Yeah. It was just amazing.

Heath Fletcher:

And he gave it everything. He invested everything he had into it, which is really, you know, at the end of the line, what a call to get at the end of that out

Kevin Scanlon:

that day. And he listened. And he listened. That was the key. Listened.

Kevin Scanlon:

He listened to the investors. He listened to the mentors. He listened to Mhmm. And he pulled it together. It took him about five to seven years.

Heath Fletcher:

But worth it in the end.

Kevin Scanlon:

It was. It was definitely worth it.

Heath Fletcher:

Wow. Wow. What a great what a great story. And so the these organizations are still bringing in, taking in applications. It's it's it's not stopping anytime soon.

Heath Fletcher:

So anybody that's got an idea. And the other thing too is that it's not it's not as any specific types of businesses or industries or you you're kind of open to a lot of different ideas.

Kevin Scanlon:

We we prefer technology. We prefer intellectual property around it. We don't do pizza restaurants or bowling alleys.

Heath Fletcher:

Oh, right. Yeah. Of course. Yes.

Kevin Scanlon:

But, you know, if it's technology and it is protected by intellectual property, we're very happy to look at it, talk to you, ment to you, keep involved with you, and follow on with you. You know? Sometimes you're not quite ready, so, you know, get back to us in six months. Tell us your progress.

Heath Fletcher:

And that's that goes for both Pasadena Angels and Tech Coast Angels. Yeah. They're both the same philosophy.

Kevin Scanlon:

That's good. They're starting to develop now incubators to bring companies in to incubate so that we can watch them.

Heath Fletcher:

Smart idea. Yeah. That's a smart idea. Now Tech sorry. Go ahead.

Kevin Scanlon:

Tech Coast Angels has an incubator that they can follow the the companies very closely.

Heath Fletcher:

See, that's a great idea. And I was just looking at the book too. Hybrid is your book. The Hybrid Entrepreneur.

Kevin Scanlon:

Yes.

Heath Fletcher:

Available on Amazon. I'm gonna get that. There it is. Of course, I need a signed copy.

Kevin Scanlon:

I'll be glad to send you one.

Heath Fletcher:

Well, Kevin, this has been really fantastic. I really appreciate your time with me today. Great stories, great insight. I'm sure there's a lot of takeaways on this. Any last words or comments you wanna pass on to people?

Kevin Scanlon:

Your your character is your destiny. It's written in in Delphi, Greece, the entrance to Delphi. And I think that's the most important yeah. Your character is your destiny.

Heath Fletcher:

I like that. That's a great one to end with. And besides your own book, any other books or or things that you find are helpful in people in your in in in in investing or becoming an entrepreneur?

Kevin Scanlon:

You have to go back and look at why was Apple so successful? Why was Microsoft soft so sick oh, why was Hewlett Packard so successful? It's the combination of business and technology.

Heath Fletcher:

Right.

Kevin Scanlon:

Genentech had a professor of molecular biology at University of San Francisco and an investment banker forty years ago sit down and have a cup of coffee. Can you imagine what the conversation was like?

Heath Fletcher:

Wow. No kidding.

Kevin Scanlon:

They were able to communicate. The investment banker was able to convince the scientists that they could commercialize gene cloning. They made the insulin gene. They cure helped cure diabetes, and they created Genentech. These are people of different cultures.

Heath Fletcher:

Completely different planets, basically.

Kevin Scanlon:

Yes. Yes. Yeah. And if they can do it

Heath Fletcher:

Yeah. So you just found a common thread and and went with it.

Kevin Scanlon:

Yep.

Heath Fletcher:

And then, of course, like we said before, personality and character, again, that ties back to what we were talking about before. So great takeaways from this and great advice. Kevin, thank you so much for being with me here today. Good. And we'll talk again soon.

Heath Fletcher:

What an awesome conversation I just had with Kevin. Great guy. Great sense of humor. That was fun and informational. I learned a lot.

Heath Fletcher:

Hope you did too. Particularly, if you're an entrepreneur looking for money, there's a couple organizations you can look into, Pasadena Angels and Tech Coast Angels. But remember, they are looking for personality and character. Character is your destiny, and, you need to be aware that they are watching to see how you engage with your management team and if you are, able to trust other people with your product, business, or service that you are, and your vision. It's a very important, aspect of all business, actually.

Heath Fletcher:

If you can't trust your investors, you can probably can't trust your employees. And there go your culture in the process. So lots to learn as an entrepreneur and don't forget to pick up Kevin's book, The Hybrid Entrepreneur, a novel career in science and business. That's a good read. I'm gonna get that book.

Heath Fletcher:

It sounds great. Thank you for listening again, and stay tuned and stay healthy.

Episode Video

Creators and Guests

Heath Fletcher
Host
Heath Fletcher
With over 30 years in creative marketing and visual storytelling, I’ve built a career on turning ideas into impact. From brand transformation to media production, podcast development, and outreach strategies, I craft compelling narratives that don’t just capture attention—they accelerate growth and drive measurable results.
Dr. Kevin Scanlon
Guest
Dr. Kevin Scanlon
Dr. Kevin Scanlon is a seasoned leader in life sciences, with a career spanning academic medicine, executive roles in biotech and pharma, and active angel investing. Recognized by LA Techweek for his impact on the Los Angeles tech and business landscape, he served as Chairman of the Pasadena Angels, where nearly 100 investors funded over 50 companies during his tenure. Dr. Scanlon has led four biotech companies as CEO, including Melanoma Diagnostics, acquired by Myriad Genetics. At Berlex-Schering AG, he oversaw global genomic and oncology programs across the US, Europe, and Asia. His academic credentials include being a Leukemia Society Scholar, recipient of the Paul Martini Medical Research Prize (Germany), and co-founding editor of Cancer Gene Therapy (Nature Publishing Group). He has served as President of the International Society of Cell and Gene Therapy and authored 139 peer-reviewed papers, nine medical books, and seven U.S. patents. Dr. Scanlon is also the author of The Hybrid Entrepreneur.